U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ® ...

Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins

Tectonic Therapeutic (NASDAQ:TECX) used a virtual key opinion leader (KOL) event to outline its strategy for hereditary ...
Investing.com Australia

Armata Pharmaceuticals stock gains on FDA designation

Armata Pharmaceuticals Inc (NYSE American:ARMP) shares rose 3.1% in premarket trading Monday after the company announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease ...